VOYA Investment Management’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,351
| Closed | -$280K | – | 2553 |
|
|
2026
Q1 | $280K | Buy |
8,351
+245
| +3% | +$9.61K | ﹤0.01% | 1981 |
|
|
2025
Q4 | $375K | Buy |
8,106
+802
| +11% | +$44K | ﹤0.01% | 1876 |
|
|
2025
Q3 | $494K | Sell |
7,304
-107,594
| -94% | -$7.98M | ﹤0.01% | 1768 |
|
|
2025
Q2 | $9.63M | Buy |
114,898
+107,913
| +1,545% | +$8.08M | 0.01% | 742 |
|
|
2025
Q1 | $499K | Sell |
6,985
-389
| -5% | -$18.9K | ﹤0.01% | 1874 |
|
|
2024
Q4 | $331K | Buy |
7,374
+89
| +1% | +$4.61K | ﹤0.01% | 2147 |
|
|
2024
Q3 | $368K | Sell |
7,285
-79
| -1% | -$3.78K | ﹤0.01% | 2159 |
|
|
2024
Q2 | $300K | Buy |
+7,364
| New | +$312K | ﹤0.01% | 2257 |
|
|
2021
Q2 | – | Sell |
-1,922
| Closed | -$36K | – | 2889 |
|
|
2021
Q1 | $36K | Hold |
1,922
| – | – | ﹤0.01% | 2757 |
|
|
2020
Q4 | $56K | Buy |
1,922
+716
| +59% | +$20.7K | ﹤0.01% | 2647 |
|
|
2020
Q3 | $45K | Buy |
+1,206
| New | +$35.2K | ﹤0.01% | 2439 |
|
VOYA Investment Management's SLNO Position: Q2 2026 in Review
VOYA Investment Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 8,351 shares — an estimated $280K sold.
VOYA Investment Management first reported a position in SLNO in Q3 2020 and held it in 11 quarters. The position peaked at $9.63M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- VOYA Investment Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- VOYA Investment Management sold 8,351 Soleno Therapeutics shares in Q2 2026, an estimated $280K.
- VOYA Investment Management first reported a position in Soleno Therapeutics in Q3 2020 and held it in 11 quarters.
- VOYA Investment Management's Soleno Therapeutics position peaked at $9.63M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.